Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Akihiro Iguchi is active.

Publication


Featured researches published by Akihiro Iguchi.


Journal of Medical Genetics | 2001

Novel mutations of FOXP3 in two Japanese patients with immune dysregulation, polyendocrinopathy, enteropathy, X linked syndrome (IPEX)

Ichiro Kobayashi; Reza Shiari; Masafumi Yamada; Nobuaki Kawamura; Motohiko Okano; Asao Yara; Akihiro Iguchi; Nobuyoshi Ishikawa; Tadashi Ariga; Yukio Sakiyama; Hans D Ochs; Kunihiko Kobayashi

Editor—Immune dysregulation, polyendocrinopathy, enteropathy, X linked syndrome (IPEX), also known as X linked autoimmunity-allergic dysregulation syndrome (XLAAD), is characterised by enteropathy and involvement of the endocrine system, such as insulin dependent diabetes mellitus (IDDM) and thyroiditis, which develop in association with autoantibodies in early infancy (MIM 304930, 304790).1 2 IPEX has been mapped to chromosome Xp11.23-Xq13.3.3 4 Recent studies have indicated that FOXP3 , a member of forkhead/winged-helix proteins, is a causative gene for both IPEX and an equivalent mouse, scurfy .5-8 Human FOXP3 consists of 11 exons and encodes 431 amino acids containing a zinc finger (Zn) domain, a leucine zipper (Zip) motif, and a forkhead domain.6 8 We have previously reported two unrelated Japanese patients with X linked autoimmune enteropathy associated with tubulonephropathy and endocrinopathy.2 9 10 We report here novel mutations in the FOXP3 gene of these patients. Clinical and laboratory findings of our patients have been previously reported.2 9 10 Briefly, patient 1, a boy, now 11 years old, was diagnosed as having autoimmune …


Blood | 2013

ANKRD26 -related thrombocytopenia and myeloid malignancies

Patrizia Noris; Rémi Favier; Marie Christine Alessi; Amy E. Geddis; Shinji Kunishima; Paula G. Heller; Paola Giordano; Karen Y. Niederhoffer; James B. Bussel; Gian Marco Podda; Nicola Vianelli; Rogier Kersseboom; Alessandro Pecci; Chiara Gnan; Caterina Marconi; Anne Auvrignon; William Cohen; Jennifer C. Yu; Akihiro Iguchi; Allison Imahiyerobo; Françoise Boehlen; Dorsaf Ghalloussi; Daniela De Rocco; Pamela Magini; Elisa Civaschi; Ginevra Biino; Marco Seri; Anna Savoia; Carlo L. Balduini

To the editor: Since the discovery that mutations in the 5′ untranslated region (UTR) of ANKRD26 are responsible for an autosomal-dominant form of thrombocytopenia ( ANKRD26 -RT),[1][1] 21 affected families were reported.[2][2] A study analyzing this series of patients suggested that ANKRD26 -RT


Bone Marrow Transplantation | 1999

Neurological complications after stem cell transplantation in childhood

Akihiro Iguchi; Ryouji Kobayashi; Makoto Yoshida; Makoto Kaneda; N Watanabe; Yuko Cho; Hideki Arioka; Naito H; Takaaki Shikano; Yorikazu Ishikawa

We analyzed the incidence of neurological complications in 77 patients receiving stem cell transplantation (SCT), and 12 patients (15.8%) had the following symptoms: convulsions, intracranial hemorrhage, and leukoencephalopathy. Although statistically not significant, neurological complications were seen more frequently in patients after allogeneic transplantation, and in those with acute graft-versus-host disease (GVHD) exceeding grade II. The most significant risk factor for neurological complications was identified as unrelated donor allogenic transplantation (P = 0.016). Complications were categorized into three groups, based on time of onset and symptoms: (1) convulsions during the conditioning period, (2) intracranial hemorrhage during the period of granulocyte recovery, and (3) leukoencephalopathy at around 2 months after SCT. We propose awareness of the risks of neurological complications in each period after SCT so that immediate and effective treatment of patients can be instigated.


Bone Marrow Transplantation | 2001

Vascular endothelial growth factor (VEGF) is one of the cytokines causative and predictive of hepatic veno-occlusive disease (VOD) in stem cell transplantation.

Akihiro Iguchi; Ryouji Kobayashi; Makoto Yoshida; K Kobayashi; K Matsuo; I Kitajima; I Maruyama

Hepatic veno-occlusive disease (VOD) is one of the most serious complications in patients receiving stem cell transplantation (SCT). However, the cause of VOD remained to be elucidated. Vascular endothelial growth factor (VEGF) has been reported to have various physiological effects including neovascularization and acceleration of vasopermeability. Because we postulated that VEGF could be one of the causative factors in VOD after SCT, serum VEGF levels were measured by ELISA in 50 patients receiving SCT. Six of the patients showed typical manifestations of VOD and four of them died due to VOD. The mean maximum serum VEGF level in the six patients with VOD was markedly increased compared to that in the patients without VOD (P < 0.001) and in normal controls (P < 0.001). Moreover, the mean maximum serum VEGF level in patients with VOD before conditioning chemoradiotherapy for SCT was also high compared to patients without VOD (P = 0.0012) in the same period. Similarly, serum VEGF levels were significantly higher in patients whose plasma protein C activities decreased below 40% (P < 0.001). during the clinical course of VOD after SCT, the increase of serum VEGF synchronized fairly well with the development of VOD. Since VEGF causes the expression of tissue factor on circulating monocyte/ macrophages and results in hypercoagulability, our observation suggests that in the patients with VOD who showed high serum VEGF it might account for the development of VOD. Furthermore, this observation may indicate a novel therapeutic strategy for prevention of VOD. Bone Marrow Transplantation (2001) 27, 1173–1180.


Cancer Medicine | 2013

IKZF1 deletion is associated with a poor outcome in pediatric B-cell precursor acute lymphoblastic leukemia in Japan

Daisuke Asai; Toshihiko Imamura; So-ichi Suenobu; Akiko Saito; Daiichiro Hasegawa; Takao Deguchi; Yoshiko Hashii; Kimikazu Matsumoto; Hirohide Kawasaki; Hiroki Hori; Akihiro Iguchi; Yoshiyuki Kosaka; Koji Kato; Keizo Horibe; Keiko Yumura-Yagi; Junichi Hara; Megumi Oda

Genetic alterations of Ikaros family zinc finger protein 1 (IKZF1), point mutations in Janus kinase 2 (JAK2), and overexpression of cytokine receptor‐like factor 2 (CRLF2) were recently reported to be associated with poor outcomes in pediatric B‐cell precursor (BCP)‐ALL. Herein, we conducted genetic analyses of IKZF1 deletion, point mutation of JAK2 exon 16, 17, and 21, CRLF2 expression, the presence of P2RY8‐CRLF2 fusion and F232C mutation in CRLF2 in 202 pediatric BCP‐ALL patients newly diagnosed and registered in Japan Childhood Leukemia Study ALL02 protocol to find out if alterations in these genes are determinants of poor outcome. All patients showed good response to initial prednisolone (PSL) treatment. Ph+, infantile, and Down syndrome–associated ALL were excluded. Deletion of IKZF1 occurred in 19/202 patients (9.4%) and CRLF2 overexpression occurred in 16/107 (15.0%), which are similar to previous reports. Patients with IKZF1 deletion had reduced event‐free survival (EFS) and overall survival (OS) compared to those in patients without IKZF1 deletion (5‐year EFS, 62.7% vs. 88.8%, 5‐year OS, 71.8% vs. 90.2%). Our data also showed significantly inferior 5‐year EFS (48.6% vs. 84.7%, log rank P = 0.0003) and 5‐year OS (62.3% vs. 85.4%, log rank P = 0.009) in NCI‐HR patients (n = 97). JAK2 mutations and P2RY8‐CRLF2 fusion were rarely detected. IKZF1 deletion was identified as adverse prognostic factor even in pediatric BCP‐ALL in NCI‐HR showing good response to PSL.


Leukemia & Lymphoma | 1997

AGGRESSIVE NATURAL KILLER (NK) CELL LYMPHOMA : REPORT OF A PEDIATRIC CASE AND REVIEW OF THE LITERATURE

Kei Ohnuma; Toyoda Y; Hirokazu Nishihira; Akihiro Iguchi; Honda K; Takeshi Nagao; Hisato Kigasawa; Tanaka Y; Kikuta H

We report a rare pediatric case of aggressive natural killer (NK) cell lymphoma, characterized by acute onset hepatosplenomegaly and respiratory distress, and infiltration by large granular lymphocytes with the phenotype of CD3-CD16-CD56+. The patient has remained in complete remission after short-pulse intensive chemotherapy, and myeloablative therapy followed by allogeneic bone marrow transplantation. We compare our case with 7 other children with NK cell leukemia reported from other institutions.


Pediatrics International | 2007

Stem cell transplantation in primary immunodeficiency disease patients

Tomonobu Sato; Ryoji Kobayashi; Nariaki Toita; Makoto Kaneda; Norikazu Hatano; Akihiro Iguchi; Nobuaki Kawamura; Tadashi Ariga

Background: Primary immunodeficiency diseases (PID) are rare but have a high associated risk of death from overwhelming infection in early childhood. Stem cell transplantation (SCT) can be curative for PID, but standardized protocols for each disease have not yet been established.


Bone Marrow Transplantation | 2004

Hyponatremia and syndrome of inappropriate antidiuretic hormone secretion complicating stem cell transplantation

Ryouji Kobayashi; Akihiro Iguchi; M Nakajima; Tomonobu Sato; M Yoshida; Makoto Kaneda; Y Suzuki; E Mino; F Kuroki; K Kobayashi

Summary:Hyponatremia is a common electrolyte disorder in hospitalized patients. Although there are a few case reports of hyponatremia following stem cell transplantation (SCT), no reports concerning the incidence are currently available. We describe the occurrence of hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) following SCT. In a single center analysis of 140 patients, hyponatremia and SIADH were observed in 40 and 11.4% of patients, respectively, following SCT. Risk factors for SIADH included young age, transplantation from an HLA-mismatched or unrelated donor, cord blood transplantation, and graft-versus-host disease prophylaxis with methyl prednisolone. Multivariate analysis revealed that transplantation from an HLA-mismatched donor and performance of SCT in a child below 4 years of age were risk factors for SIADH. For patients who underwent SCT from an HLA-mismatched or unrelated donor, those with SIADH showed a significantly higher overall survival rate (90.9 vs 40.2%) and event-free survival rate (77.8 vs 33.8%) compared to those without SIADH. Overall, our data show that hyponatremia and SIADH are relatively common complications following SCT, especially in children below 4 years of age and after SCT from an HLA-mismatched donor.


Bone Marrow Transplantation | 2005

Significance of eosinophilia after stem cell transplantation as a possible prognostic marker for favorable outcome

Tomonobu Sato; Ryouji Kobayashi; M Nakajima; Akihiro Iguchi; Tadashi Ariga

Summary:Although eosinophilia after stem cell transplantation (SCT) has been addressed in recent reports, the significance of eosinophilia in disease outcome after SCT has not been well studied. In this study, we investigate the frequency of eosinophilia after SCT to determine its prognostic value. The subjects were 113 patients with malignant or nonmalignant diseases who underwent SCT treatment. In these patients, eosinophilia was detected in 44 cases (38.9%), on average 67.5 days after transplantation, and the mean maximum absolute eosinophil count was 840.5 × 106/l. To study the basis of eosinophilia after SCT, various serum cytokine levels during SCT in patients both with and without eosinophilia were analyzed. Statistical analysis indicated that the overall patient survival rates improved in those with eosinophilia compared to those without eosinophilia (88.7 vs 43.0%, P=0.0034). In particular, in patients with malignant diseases, those with eosinophilia showed a higher event-free survival (81.1 vs 44.6%, P=0.0025) and a lower relapse rate (16.0 vs 43.0%, P=0.0287) than those without eosinophilia. In conclusion, we propose that eosinophilia after SCT could be a useful prognostic marker for determining favorable outcomes in patients with malignant diseases. The reasons for this good prognosis in SCT patients with eosinophilia are discussed.


Pediatric Blood & Cancer | 2011

Piperacillin/tazobactam versus cefozopran for the empirical treatment of pediatric cancer patients with febrile neutropenia

Mizuho Ichikawa; Daisuke Suzuki; Junjiro Ohshima; Yuko Cho; Makoto Kaneda; Akihiro Iguchi; Tadashi Ariga

The aim of this study was to evaluate the efficacy and safety of piperacillin/tazobactam (PIP/TAZO) and cefozopran (CZOP) monotherapy in pediatric cancer patients with febrile neutropenia (FN).

Collaboration


Dive into the Akihiro Iguchi's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge